An integrated biomanufacturing platform bridging lab and market

Designing Nature Building Tomorrow

Lab-to-Market

Bridging

Precision-fermentation cell factories for commercial-scale production of high-value functional ingredients

Core Competencies

An end-to-end commercialization system built to bridge the valley of death from research to market

R&D led by Sang Yup Lee, Distinguished Professor at KAIST and a world-renowned leader in synthetic biology.

Proven research and technology development capabilities support a portfolio of high-value pipelines positioned for rapid commercialization.

Drawing on hands-on industrial experience in taking R&D into products, we translate research outcomes into customer-ready product specifications.
Reproducibility, stability, and Assay/QC standards are built in from the start, enabling rapid performance validation and customer PoC completion at pilot scale.

Built on CJ BIO experience in process development and commercial-scale manufacturing, we co-optimize titer, yield, productivity, and COGS from the outset to systematically de-risk scale-up.

Our end-to-end commercialization capabilities connect production, purification, QC/QA, regulatory, and supply chain—turning pilot success into scalable supply, customer contracts, and revenue.

Fermentation-Based
Lutein

Fermentation-Based
Lutein

0~3
years
Market Entry
Phase 1

Asset-light Commercialization

Standardized process package

Standardize fermentation and DSP processes to ensure consistent quality and lot-to-lot reproducibility. Package each process for seamless technology transfer to accelerate commercialization.

Selective Early Out-Licensing

Strategically out-license product- or market-specific rights at an early stage to generate upfront and recurring royalty revenue while retaining core technology assets and long-term business value.

Demonstration-scale validation

Validate process robustness, reproducibility, and commercial manufacturability through demonstration-scale production, laying the foundation for large-scale manufacturing and global partnerships.

Standardized process packageSelective Early Out-LicensingDemonstration-scale validation
Value Expansion
Phase 2

Hybrid Revenue & Scale-Up

Direct sales of high-value ingredients

Generate stable revenue through direct sales of proprietary bio-based ingredients, while leveraging differentiated technologies to strengthen both market competitiveness and profitability.

Global scale-up partnerships

Scale production through expanded collaboration with global partners and accelerate international market entry through technology transfer and joint commercialization.

In-House or Public–Private Manufacturing Capacity

Secure dedicated manufacturing capacity through in-house, partner-operated, or public–private facilities as commercial demand scales.

Direct sales of high-value ingredientsGlobal scale-up partnershipsIn-House or Public–Private Manufacturing Capacity
Global Platform
Phase 3

SynBio Commercialization Platform

End-to-End SynBio Foundry

An integrated manufacturing platform for custom processes and commercial-scale production.

High-Margin Royalty & Platform Revenue

Grow licensing and platform businesses for royalty and recurring revenue.

Global Top-Tier in Precision Biomanufacturing

Scale through technology, partnerships, and a broader commercial portfolio.

End-to-End SynBio FoundryHigh-Margin Royalty & Platform RevenueGlobal Top-Tier in Precision Biomanufacturing

실리코바이오는 한국형 정밀발효 스케일업 인프라를 설계하는 앵커기업이 되고자 합니다.

  1. National R&D: industrial-scale lutein biomanufacturing (participating institution)

    National R&D: industrial-scale lutein biomanufacturing (participating institution)

  2. National R&D: microbial-lysate functional protein (participating institution)

    National R&D: microbial-lysate functional protein (participating institution)

  3. National R&D: AI-enabled alternative protein (participating institution)

    National R&D: AI-enabled alternative protein (participating institution)

  4. Pre-A financing — Encore Future Growth New Technology Fund

    Pre-A financing — Encore Future Growth New Technology Fund

  5. TIPS Deep Tech Track

    TIPS Deep Tech Track

  6. Operator, Global Innovation Zone for SynBio biomanufacturing

    Operator, Global Innovation Zone for SynBio biomanufacturing

  7. Seed financing — Medytox Venture Investment, KAIST Holdings

    Seed financing — Medytox Venture Investment, KAIST Holdings

  8. Company founded

    Company founded

  9. Startup KAIST Global Studio, Cohort 2

    Startup KAIST Global Studio, Cohort 2

  10. Deep-science startup support program

    Deep-science startup support program

SilicoBio

RESEARCH & NEWS

Papers and coverage related to KAIST–SilicoBio. Matching stories share one headline; click an outlet name for the original.

Publications

5

News

6 / 6 stories
Field
Type
Region
Sort

Contact Us

SilicoBio — synthetic biology for global-scale biomanufacturing

Privacy Policy

SilicoBio Co., Ltd. (the “Company”) complies with Korea’s Personal Information Protection Act and other applicable privacy laws. This Privacy Policy explains how we collect, use, and protect personal information.

This Policy applies from the effective date below. If we change it, we will post notice on our website at least seven days before the change takes effect.

This Policy applies to the website we operate at https://www.silicobio.com/.


1. Why we collect personal information

We collect and use personal information only for the purposes below. We do not use it for anything else. If the purpose changes, we will ask for your consent first.

  • Receiving and responding to inquiries submitted through our website

2. How long we keep it
  • Website inquiries: 1 year from the date we finish handling the inquiry

3. Sharing with third parties

We do not share your personal information with third parties without your consent.


4. Service providers

We use the following company to process personal information on our behalf.

ProviderRole
Resend, Inc.Sending inquiry emails

Our contract with the provider requires them to follow privacy law, not disclose the information to others, and take responsibility if they fail to do so. If we change providers, we will update this Policy.


5. Transfers outside Korea

We transfer personal information outside Korea as follows.

RecipientCountryInformation transferredWhen and howPurposeRetention period
Resend, Inc.United StatesCompany name, email address, inquiry, and name (if provided)Sent over the internet when you submit an inquirySending inquiry emailsThe period in Section 2

Legal basis: Article 28-8(1)(3) of the Personal Information Protection Act.

If you do not want your information transferred abroad, please do not submit an inquiry. In that case, you will not be able to use the website contact form.


6. Your rights

You may at any time ask us to access, correct, or delete your personal information, stop processing it, or withdraw your consent.

Send your request in writing or by email to the privacy officer below. We will respond within 10 days of receiving it.


7. Information we collect
  • Required: company name, email address, inquiry
  • Optional: name
  • Collected automatically: IP address, browser type, date and time of visit

8. How we delete information

When the retention period ends or we no longer need the information, we delete it without delay. Electronic files are permanently deleted so they cannot be recovered. Paper records are shredded or incinerated.


9. Security
  • Administrative: internal privacy procedures; access limited to people who need it
  • Technical: access controls; HTTPS encryption in transit
  • Physical: locked storage of records that contain personal information

10. Complaints and dispute resolution

If you believe your personal information has been mishandled, you may contact the following Korean authorities for mediation or advice.

  • Personal Information Infringement Report Center: 118 (no area code)
  • Personal Information Dispute Mediation Committee: 1833-6972
  • Supreme Prosecutors’ Office: 1301 (no area code)
  • Korean National Police Agency: 182 (no area code)

11. Privacy officer
  • Privacy officer: Sol Choi, CEO
  • Email: contact@silicobio.com
  • Address: 9, Yuseong-daero 1205beon-gil, Yuseong-gu, Daejeon, Republic of Korea (Jaun-dong)

12. Changes to this Policy

This Privacy Policy is effective as of August 30, 2026.